MorphoSys AG
https://www.morphosys.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MorphoSys AG
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout
The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.
LENZ Sees Big Commercial Market After Presbyopia Trial Success
LENZ announced successful results from its Phase III pivotal trial of LNZ100 and plans to apply for US FDA approval in the middle of this year, with commercialization in Q2 2025.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Lanthio Pharma B.V.
- MorphoSys US Inc.
- Sloning BioTechnology
- Constellation Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice